Donald Wuchterl
Direktor/Vorstandsmitglied bei ABEONA THERAPEUTICS INC.
Vermögen: 239 815 $ am 30.04.2024
Aktive Positionen von Donald Wuchterl
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ABEONA THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 19.04.2021 | - |
Independent Dir/Board Member | 19.04.2021 | - | |
T-Knife Therapeutics, Inc. | Corporate Officer/Principal | - | - |
Karriereverlauf von Donald Wuchterl
Ehemalige bekannte Positionen von Donald Wuchterl
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AUDENTES THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2016 | 01.01.2021 |
Cytovance Biologics, Inc.
Cytovance Biologics, Inc. BiotechnologyHealth Technology Cytovance Biologics, Inc. operates as a biopharmaceutical contract manufacturing company. It specializes in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. Its services include Cell Line Selection, Cell Culture, Recovery and Purification, Analytical development, Troubleshooting Existing Processes, Final Product Fill and Finish, Technology Transfer, Microbial Fermentation, Purification, Cell banking and storage, and Project management. The company was founded in 2003 and is headquartered in Oklahoma City, OK. | Geschäftsführer | - | - |
Ausbildung von Donald Wuchterl
Fitchburg State University | Masters Business Admin |
Colorado Technical University, Inc. | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
Corporate Officer/Principal | 2 |
Director/Board Member | 1 |
Independent Dir/Board Member | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ABEONA THERAPEUTICS INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Astellas Gene Therapies, Inc.
Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Cytovance Biologics, Inc.
Cytovance Biologics, Inc. BiotechnologyHealth Technology Cytovance Biologics, Inc. operates as a biopharmaceutical contract manufacturing company. It specializes in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. Its services include Cell Line Selection, Cell Culture, Recovery and Purification, Analytical development, Troubleshooting Existing Processes, Final Product Fill and Finish, Technology Transfer, Microbial Fermentation, Purification, Cell banking and storage, and Project management. The company was founded in 2003 and is headquartered in Oklahoma City, OK. | Health Technology |
T-Knife Therapeutics, Inc. |
- Börse
- Insiders
- Donald Wuchterl
- Erfahrung